Trials / Completed
CompletedNCT03418545
A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital Hollowing
A Multicenter, Single-blind, Randomized, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLBELLA® XC Injectable Gel for Correction of Infraorbital Hollowing
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 163 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 22 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM® VOLBELLA™ XC in adult participants seeking correction of hollowing of the tear troughs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | JUVÉDERM VOLBELLA® XC injectable gel | JUVÉDERM® VOLBELLA™ XC dermal filler injected into the infraorbital and adjacent area. |
Timeline
- Start date
- 2018-01-26
- Primary completion
- 2018-10-17
- Completion
- 2019-08-22
- First posted
- 2018-02-01
- Last updated
- 2021-11-15
- Results posted
- 2021-11-15
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03418545. Inclusion in this directory is not an endorsement.